$FGEN
FIBROGEN INC Stock $fgen

$fgen Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000156459021009871 Filed on March 01, 2021

Income Statement

Concept	2020 Q4	2020	2019 Q4
Revenue	$65.00M	$176.3M	$8.000M
YoY Change	712.5%	-31.28%	-92.6%
Cost Of Revenue	$2.600M	$8.869M	$900.0K
YoY Change	188.89%	673.23%
Gross Profit	$62.40M	$167.5M	$7.100M
YoY Change	778.87%	-34.44%
Gross Profit Margin	96.0%	94.97%	88.75%
Selling, General & Admin	$40.10M	$97.20M	$48.40M
YoY Change	-17.15%	-28.25%	170.39%
% of Gross Profit	64.26%	58.05%	681.69%
Research & Development	$78.10M	$0.00	$56.80M
YoY Change	37.5%	-100.0%	-19.2%
% of Gross Profit	125.16%	0.0%	800.0%
Depreciation & Amortization	$5.490M	$11.70M	$5.010M
YoY Change	9.58%	5.41%	167.91%
% of Gross Profit	8.8%	6.99%	70.56%
Operating Expenses	$120.4M	$0.00	$107.5M
YoY Change	12.0%	-100.0%	22.02%
Operating Profit	-$58.00M	-$191.9M	-$100.4M
YoY Change	-42.23%	114.84%
Interest Expense	-$500.0K	$2.402M	$2.400M
YoY Change	-120.83%	-16.48%	140.0%
% of Operating Profit
Other Income/Expense, Net		$5.553M
YoY Change		-64.28%
Pretax Income	-$58.50M	-$188.7M	-$98.10M
YoY Change	-40.37%	146.25%	-567.14%
Income Tax	$200.0K	$360.0K	$100.0K
% Of Pretax Income
Net Earnings	-$58.60M	-$189.3M	-$98.10M
YoY Change	-40.27%	145.93%	-567.14%
Net Earnings / Revenue	-90.15%	-107.36%	-1226.25%
Basic Earnings Per Share		-$2.11
Diluted Earnings Per Share	-$642.5K	-$2.106M	-$1.133M
COMMON SHARES
Basic Shares Outstanding		89.85M
Diluted Shares Outstanding		89.85M

Balance Sheet

Concept	2020 Q4	2020	2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$686.5M	$686.5M	$533.8M
YoY Change	28.61%	28.61%	-14.1%
Cash & Equivalents	$678.4M	$590.3M	$126.3M
Short-Term Investments	$8.100M	$8.100M	$407.5M
Other Short-Term Assets	$1.807M	$10.20M	$1.717M
YoY Change	5.24%	24.39%	-22.8%
Inventory	$16.53M	$16.50M	$6.887M
Prepaid Expenses	$8.353M		$6.464M
Receivables	$41.88M	$46.00M	$28.46M
Other Receivables	-$4.100M	-$4.100M	-$4.800M
Total Short-Term Assets	$755.1M	$755.1M	$702.5M
YoY Change	7.49%	7.49%	1.81%
LONG-TERM ASSETS
Property, Plant & Equipment	$33.65M	$65.30M	$42.74M
YoY Change	-21.28%	-22.54%	-66.4%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$2.728M	$3.000M	$61.10M
YoY Change	-95.54%	-95.09%	9.5%
Other Assets	$1.390M	$3.500M	$9.372M
YoY Change	-85.17%	-63.16%	174.04%
Total Long-Term Assets	$71.73M	$71.70M	$154.9M
YoY Change	-53.69%	-53.71%	-18.72%
TOTAL ASSETS
Total Short-Term Assets	$755.1M	$755.1M	$702.5M
Total Long-Term Assets	$71.73M	$71.70M	$154.9M
Total Assets	$826.8M	$826.8M	$857.4M
YoY Change	-3.56%	-3.57%	-2.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$24.79M	$24.80M	$6.088M
YoY Change	307.18%	306.56%	-33.38%
Accrued Expenses	$118.3M	$104.4M	$83.82M
YoY Change	41.18%	24.58%	26.76%
Deferred Revenue	$6.547M		$490.0K
YoY Change	1236.12%		-96.44%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$12.30M	$12.30M	$12.40M
YoY Change	-0.81%	-0.81%
Total Short-Term Liabilities	$163.2M	$163.2M	$102.7M
YoY Change	58.83%	58.91%	15.4%
LONG-TERM LIABILITIES
Long-Term Debt	$44.10M	$44.10M	$55.50M
YoY Change	-20.54%	-20.54%	-51.32%
Other Long-Term Liabilities	$38.79M	$169.4M	$65.41M
YoY Change	-40.7%	3.48%	554.53%
Total Long-Term Liabilities	$38.79M	$213.5M	$65.41M
YoY Change	-40.7%	-2.6%	554.53%
TOTAL LIABILITIES
Total Short-Term Liabilities	$163.2M	$163.2M	$102.7M
Total Long-Term Liabilities	$38.79M	$213.5M	$65.41M
Total Liabilities	$385.4M	$404.7M	$322.0M
YoY Change	19.69%	18.58%	-8.56%
SHAREHOLDERS EQUITY
Retained Earnings	-$974.0M		-$784.7M
YoY Change	24.12%		9.62%
Common Stock	$914.0K		$877.0K
YoY Change	4.22%		2.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$422.2M	$422.2M	$516.1M
YoY Change
Total Liabilities & Shareholders Equity	$826.8M	$826.8M	$857.4M
YoY Change	-3.56%	-3.57%	-2.63%

Cashflow Statement

Concept	2020 Q4	2020	2019 Q4
OPERATING ACTIVITIES
Net Income	-$58.60M	-$189.3M	-$98.10M
YoY Change	-40.27%	145.93%	-567.14%
Depreciation, Depletion And Amortization	$5.490M	$11.70M	$5.010M
YoY Change	9.58%	5.41%	167.91%
Cash From Operating Activities	-$7.230M	$81.60M	-$45.05M
YoY Change	-83.95%	-203.68%	158.02%
INVESTING ACTIVITIES
Capital Expenditures	-$2.390M	$3.994M	-$1.740M
YoY Change	37.36%	-30.68%	-45.11%
Acquisitions
YoY Change
Other Investing Activities	$146.2M	$456.5M	-$23.29M
YoY Change	-727.57%	262.92%	-94.93%
Cash From Investing Activities	$143.8M	$452.5M	-$25.03M
YoY Change	-674.39%	277.02%	-94.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$37.83M
YoY Change		82.06%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.660M	13.34M	-280.0K
YoY Change	-2121.43%	-410.3%	-109.93%
NET CHANGE
Cash From Operating Activities	-7.230M	81.60M	-45.05M
Cash From Investing Activities	143.8M	452.5M	-25.03M
Cash From Financing Activities	5.660M	13.34M	-280.0K
Net Change In Cash	142.2M	552.1M	-70.36M
YoY Change	-302.1%	1391.91%	-85.26%
FREE CASH FLOW
Cash From Operating Activities	-$7.230M	$81.60M	-$45.05M
Capital Expenditures	-$2.390M	$3.994M	-$1.740M
Free Cash Flow	-$4.840M	$77.61M	-$43.31M
YoY Change	-88.82%	-191.88%	203.08%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2020Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	0
CY2018Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	0
CY2018Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	0
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	fgen:AccruedAndOtherCurrentLiabilitiesMember
CY2019Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	fgen:AccruedAndOtherCurrentLiabilitiesMember
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherNoncurrentLiabilitiesMember
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherNoncurrentLiabilitiesMember
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M24D
CY2019Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y7M6D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M18D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y1M6D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M6D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y6M
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y1M6D
CY2018	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	us-gaap:ProductMember
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	102745000
CY2019Q4	fgen	Accrued Product Development Costs AccruedProductDevelopmentCosts	16780000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	163187000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	126266000
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	407491000
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	28455000
CY2019Q4	us-gaap	Inventory Net InventoryNet	6887000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	133391000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	702490000
CY2019Q4	fgen	Restricted Time Deposits Noncurrent RestrictedTimeDepositsNoncurrent	2072000
CY2019Q4	us-gaap	Long Term Investments LongTermInvestments	61118000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42743000
CY2019Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	39602000
CY2020Q4	fgen	Equity Method Investment In Unconsolidated Variable Interest Entity EquityMethodInvestmentInUnconsolidatedVariableInterestEntity	2728000
CY2019Q4	fgen	Equity Method Investment In Unconsolidated Variable Interest Entity EquityMethodInvestmentInUnconsolidatedVariableInterestEntity	0
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3433000
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9372000
CY2020Q4	us-gaap	Assets Assets	826840000
CY2019Q4	us-gaap	Assets Assets	857397000
CY2020Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	1118000
CY2019Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	0
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	24789000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6088000
CY2020Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	24000
CY2019Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	36883000
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	119521000
CY2019Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	83816000
CY2020Q4	fgen	Due To Related Parties Deferred Revenue Current DueToRelatedPartiesDeferredRevenueCurrent	2907000
CY2019Q4	fgen	Due To Related Parties Deferred Revenue Current DueToRelatedPartiesDeferredRevenueCurrent	249000
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6547000
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	490000
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	12330000
CY2019Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	12351000
CY2020Q4	fgen	Due To Related Parties Deferred Revenue Noncurrent DueToRelatedPartiesDeferredRevenueNoncurrent	4636000
CY2019Q4	fgen	Due To Related Parties Deferred Revenue Noncurrent DueToRelatedPartiesDeferredRevenueNoncurrent	125000
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	125000000
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	125000000
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	91441000
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	91441000
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	87657000
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	87657000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	176319000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	256577000
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	212958000
CY2019	fgen	Cost Of Goods And Services Sold Operating Expense CostOfGoodsAndServicesSoldOperatingExpense	1147000
CY2018	fgen	Cost Of Goods And Services Sold Operating Expense CostOfGoodsAndServicesSoldOperatingExpense	0
CY2020	us-gaap	Interest Expense InterestExpense	2402000
CY2020	fgen	Unconsolidated Variable Interest Entity Investment Loss UnconsolidatedVariableInterestEntityInvestmentLoss	202000
CY2019	fgen	Unconsolidated Variable Interest Entity Investment Loss UnconsolidatedVariableInterestEntityInvestmentLoss	0
CY2018	fgen	Unconsolidated Variable Interest Entity Investment Loss UnconsolidatedVariableInterestEntityInvestmentLoss	0
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-188931000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	360000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	328000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-76970000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-86420000
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.11
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.89
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.03
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	89854000
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	86633000
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	84062000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-545000
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-3752000
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	923000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-193043000
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-76047000
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-85656000
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	547738000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-86420000
CY2018	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-7000
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	771000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	11000
CY2018	fgen	Adjustments To Additional Paid In Capital Shares Issued From Stock Plans Net Of Payroll Taxes Paid AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid	14235000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	52142000
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	528470000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-76970000
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	592000
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	331000
CY2019	fgen	Adjustments To Additional Paid In Capital Shares Issued From Stock Plans Net Of Payroll Taxes Paid AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid	7962000
CY2019	fgen	Warrants Exercised During Period Value WarrantsExercisedDuringPeriodValue	66000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-189291000
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-545000
CY2020	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3207000
CY2020	fgen	Adjustments To Additional Paid In Capital Shares Issued From Stock Plans Net Of Payroll Taxes Paid AdjustmentsToAdditionalPaidInCapitalSharesIssuedFromStockPlansNetOfPayrollTaxesPaid	26366000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	72720000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	441449000
CY2020	us-gaap	Profit Loss ProfitLoss	-189291000
CY2020	us-gaap	Depreciation Depreciation	11678000
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	10369000
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-103000
CY2020	fgen	Unrealized Loss Gain On Equity Investments UnrealizedLossGainOnEquityInvestments	0
CY2019	fgen	Unrealized Loss Gain On Equity Investments UnrealizedLossGainOnEquityInvestments	88000
CY2018	fgen	Unrealized Loss Gain On Equity Investments UnrealizedLossGainOnEquityInvestments	-1120000
CY2020	fgen	Investment Loss In Unconsolidated Variable Interest Entity InvestmentLossInUnconsolidatedVariableInterestEntity	-202000
CY2019	fgen	Investment Loss In Unconsolidated Variable Interest Entity InvestmentLossInUnconsolidatedVariableInterestEntity	0
CY2018	fgen	Investment Loss In Unconsolidated Variable Interest Entity InvestmentLossInUnconsolidatedVariableInterestEntity	0
CY2019	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	42000
CY2018	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-53000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	66267000
CY2020	fgen	Increase Decrease In Lease Obligations IncreaseDecreaseInLeaseObligations	0
CY2020	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-933000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	72720000
CY2020	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	0
CY2020	us-gaap	Availableforsale Securities Gross Realized Gain Loss Excluding Other Than Temporary Impairments AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments	-258000
CY2020	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	718000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11973000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9175000
CY2020	fgen	Increase Decrease In Prepaid Expenses And Other Current Assets Related Parties IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties	124321000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-123492000
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-6843000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	17731000
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	31048000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	52142000
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	0
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	1074000
CY2019	us-gaap	Availableforsale Securities Gross Realized Gain Loss Excluding Other Than Temporary Impairments AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments	0
CY2018	us-gaap	Availableforsale Securities Gross Realized Gain Loss Excluding Other Than Temporary Impairments AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments	87000
CY2019	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	42365000
CY2018	us-gaap	Increase Decrease In Accounts Receivable Related Parties IncreaseDecreaseInAccountsReceivableRelatedParties	-43486000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-35229000
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	55232000
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6887000
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0
CY2019	fgen	Increase Decrease In Prepaid Expenses And Other Current Assets Related Parties IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties	-125210000
CY2018	fgen	Increase Decrease In Prepaid Expenses And Other Current Assets Related Parties IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsRelatedParties	0
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	128598000
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	129000
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	3253000
CY2018	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1090000
CY2020	fgen	Increase Decrease In Accounts Payable From Related Party IncreaseDecreaseInAccountsPayableFromRelatedParty	1118000
CY2019	fgen	Increase Decrease In Accounts Payable From Related Party IncreaseDecreaseInAccountsPayableFromRelatedParty	0
CY2018	fgen	Increase Decrease In Accounts Payable From Related Party IncreaseDecreaseInAccountsPayableFromRelatedParty	0
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3051000
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3630000
CY2020	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-36859000
CY2019	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	36439000
CY2018	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	172000
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	18288000
CY2018	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	5606000
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	7169000
CY2019	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3137000
CY2018	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3908000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	45077000
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-49941000
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-5031000
CY2019	fgen	Increase Decrease In Lease Obligations IncreaseDecreaseInLeaseObligations	0
CY2018	fgen	Increase Decrease In Lease Obligations IncreaseDecreaseInLeaseObligations	32000
CY2020	fgen	Increase Decrease In Accrued Interest For Finance Lease Liabilities IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities	-177000
CY2019	fgen	Increase Decrease In Accrued Interest For Finance Lease Liabilities IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities	194000
CY2018	fgen	Increase Decrease In Accrued Interest For Finance Lease Liabilities IncreaseDecreaseInAccruedInterestForFinanceLeaseLiabilities	0
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-28236000
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	52360000
CY2018	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	1636000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-78705000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-76144000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5762000
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8020000
CY2020	fgen	Payment Made For Investment In Unconsolidated Variable Interest Entity PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity	3896000
CY2019	fgen	Payment Made For Investment In Unconsolidated Variable Interest Entity PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity	0
CY2018	fgen	Payment Made For Investment In Unconsolidated Variable Interest Entity PaymentMadeForInvestmentInUnconsolidatedVariableInterestEntity	0
CY2020	fgen	Proceeds From Equity Transfer Of Unconsolidated Variable Interest Entity ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity	1063000
CY2019	fgen	Proceeds From Equity Transfer Of Unconsolidated Variable Interest Entity ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity	0
CY2018	fgen	Proceeds From Equity Transfer Of Unconsolidated Variable Interest Entity ProceedsFromEquityTransferOfUnconsolidatedVariableInterestEntity	0
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	7000
CY2018	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	184000
CY2020	fgen	Payments To Acquire Available For Sale Securities And Term Deposit PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit	8192000
CY2019	fgen	Payments To Acquire Available For Sale Securities And Term Deposit PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit	411299000
CY2018	fgen	Payments To Acquire Available For Sale Securities And Term Deposit PaymentsToAcquireAvailableForSaleSecuritiesAndTermDeposit	576880000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	81602000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3994000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13343000
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4695000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	552127000
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	10606000
CY2019	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	0
CY2018	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	8167000
CY2020	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	456900000
CY2019	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	537072000
CY2018	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	54426000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	452487000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	120018000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-522123000
CY2020	us-gaap	Proceeds From Long Term Capital Lease Obligations ProceedsFromLongTermCapitalLeaseObligations	0
CY2019	us-gaap	Proceeds From Long Term Capital Lease Obligations ProceedsFromLongTermCapitalLeaseObligations	0
CY2018	us-gaap	Proceeds From Long Term Capital Lease Obligations ProceedsFromLongTermCapitalLeaseObligations	49000
CY2020	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	0
CY2019	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	0
CY2018	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	6000
CY2020	fgen	Repayments Of Finance Lease Liabilities RepaymentsOfFinanceLeaseLiabilities	12620000
CY2019	fgen	Repayments Of Finance Lease Liabilities RepaymentsOfFinanceLeaseLiabilities	11925000
CY2018	fgen	Repayments Of Finance Lease Liabilities RepaymentsOfFinanceLeaseLiabilities	0
CY2020	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	403000
CY2019	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	403000
CY2018	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	403000
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	11463000
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	12750000
CY2018	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	15612000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	37829000
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20778000
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	29847000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-4300000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13875000
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-5000
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-8000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	37008000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-584400000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	126266000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	174000
CY2018	us-gaap	Interest Paid Net InterestPaidNet	218000
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	460000
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	276000
CY2020	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	0
CY2019	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	0
CY2018	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	24000
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	126266000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	89258000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	673658000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	678393000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	135000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	884000
CY2020	fgen	Short Term Investments Maximum Maturity Period ShortTermInvestmentsMaximumMaturityPeriod	P12M
CY2020Q2	us-gaap	Translation Adjustment Functional To Reporting Currency Net Of Tax TranslationAdjustmentFunctionalToReportingCurrencyNetOfTax	1300000
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions include valuation and recognition of revenue. On an ongoing basis, management reviews these estimates and assumptions. Changes in facts and circumstances may alter such estimates and actual results could differ from those estimates.</p>
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks associated with concentration of credit for cash and cash equivalents. Outside of short-term operating needs, the majority of cash on hand is invested in U.S. treasuries and money market funds. Any remaining cash is deposited with major financial institutions in the U.S., Finland, China and the Cayman Islands. At times, such deposits may be in excess of insured limits. The Company has not experienced any loss on its deposits of cash and cash equivalents. Included in current assets are significant balances of accounts receivable as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.62%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas Pharma Inc. (“Astellas”)—Related party</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.62%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca AB (“AstraZeneca”)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="middle"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.94%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company started selling roxadustat in China since late 2019 through a growing number of pharmaceutical distributors located in China. As of December 31, 2019, the aggregate accounts receivable from distributors was immaterial. As of December 31, 2020, along with the growing roxadustat sales in China, the aggregate accounts receivable from distributors represented 64% of the consolidated accounts receivable, with no material balance from any individual distributor.</p>
CY2020	fgen	Highly Liquid Investment Maturity Period HighlyLiquidInvestmentMaturityPeriod	three months or less
CY2020Q4	fgen	Restricted Time Deposits Noncurrent RestrictedTimeDepositsNoncurrent	2100000
CY2019Q4	fgen	Restricted Time Deposits Noncurrent RestrictedTimeDepositsNoncurrent	2100000
CY2020	fgen	Short Term Investments Maximum Maturity Period ShortTermInvestmentsMaximumMaturityPeriod	P12M
CY2020	fgen	Long Term Investments Minimum Maturity Period LongTermInvestmentsMinimumMaturityPeriod	P12M
CY2020	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2020	us-gaap	Revenue Performance Obligation Description Of Payment Terms RevenuePerformanceObligationDescriptionOfPaymentTerms	The period between the transfer of control of the promised goods and when the Company receives payment is based on a general 60-day payment term.
CY2020	fgen	Description Of Sales Return DescriptionOfSalesReturn	Distributors can request to return product to the Company only due to quality issues or for product purchased within one year prior to the product’s expiration date
CY2020Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2018Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2018Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	0
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3	0
CY2019Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	29800000
CY2020Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2019Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2018Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2020Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2019Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2018Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2020Q4	fgen	Finance Lease Right Of Use Assets Cost FinanceLeaseRightOfUseAssetsCost	50477000
CY2019Q4	fgen	Finance Lease Right Of Use Assets Cost FinanceLeaseRightOfUseAssetsCost	49909000
CY2020Q4	fgen	Finance Lease Accumulated Amortization FinanceLeaseAccumulatedAmortization	20871000
CY2019Q4	fgen	Finance Lease Accumulated Amortization FinanceLeaseAccumulatedAmortization	10307000
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	29606000
CY2019Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	39602000
CY2020Q4	fgen	Operating Lease Right Of Use Assets Cost OperatingLeaseRightOfUseAssetsCost	3934000
CY2019Q4	fgen	Finance Lease And Operating Lease Assets FinanceLeaseAndOperatingLeaseAssets	41533000
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	12330000
CY2019Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	12351000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1188000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	983000
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	25391000
CY2019Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	37610000
CY2019Q4	fgen	Operating Lease Right Of Use Assets Cost OperatingLeaseRightOfUseAssetsCost	2736000
CY2020Q4	fgen	Operating Lease Accumulated Amortization OperatingLeaseAccumulatedAmortization	1891000
CY2019Q4	fgen	Operating Lease Accumulated Amortization OperatingLeaseAccumulatedAmortization	805000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2043000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1931000
CY2020Q4	fgen	Finance Lease And Operating Lease Assets FinanceLeaseAndOperatingLeaseAssets	31649000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	853000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	942000
CY2020Q4	fgen	Finance Lease And Operating Lease Liability FinanceLeaseAndOperatingLeaseLiability	39762000
CY2019Q4	fgen	Finance Lease And Operating Lease Liability FinanceLeaseAndOperatingLeaseLiability	51886000
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	10369000
CY2019	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	10307000
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1932000
CY2019	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	2373000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	1151000
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	891000
CY2020	us-gaap	Sublease Income SubleaseIncome	1201000
CY2019	us-gaap	Sublease Income SubleaseIncome	1385000
CY2020	us-gaap	Lease Cost LeaseCost	12251000
CY2019	us-gaap	Lease Cost LeaseCost	12186000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	951000
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	914000
CY2020	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	1896000
CY2019	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	2196000
CY2020	fgen	Repayments Of Finance Lease Liabilities RepaymentsOfFinanceLeaseLiabilities	12620000
CY2019	fgen	Repayments Of Finance Lease Liabilities RepaymentsOfFinanceLeaseLiabilities	11925000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	662000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	49909000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1072000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2736000
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0439
CY2019Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0442
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0474
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0475
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	13689000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1142000
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	13886000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	839000
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	12526000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	143000
CY2020Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	40101000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2124000
CY2020Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	2380000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	83000
CY2020Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	37721000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2041000
CY2020Q4	us-gaap	Cash Cash	88046000
CY2019Q4	us-gaap	Cash Cash	40715000
CY2020Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	590347000
CY2019Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	85551000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	678393000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	126266000
CY2020Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	8272000
CY2020Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	119000
CY2020Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3000
CY2020Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	8388000
CY2019Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	467850000
CY2019Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	784000
CY2019Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	25000
CY2019Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	468609000
CY2020Q4	fgen	Available For Sale Securities Bond And Mutual Funds Maturing Within One Year AvailableForSaleSecuritiesBondAndMutualFundsMaturingWithinOneYear	8144000
CY2020Q4	us-gaap	Available For Sale Securities Equity Securities AvailableForSaleSecuritiesEquitySecurities	244000
CY2020Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	8388000
	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2303000
CY2019Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	325000
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	8114000
CY2019Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2264000
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	6113000
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4298000
CY2020Q4	us-gaap	Inventory Net InventoryNet	16530000
CY2019Q4	us-gaap	Inventory Net InventoryNet	6887000
CY2020Q4	fgen	Percentage Of Pre Launch Inventory Capitalized Of Aggregate Inventory Balance PercentageOfPreLaunchInventoryCapitalizedOfAggregateInventoryBalance	0.29
CY2020Q4	us-gaap	Supplies Supplies	2147000
CY2019Q4	us-gaap	Supplies Supplies	180000000
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	2147000
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	54790000
CY2020Q4	fgen	Supplies Net SuppliesNet	0
CY2019Q4	fgen	Supplies Net SuppliesNet	125210000
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	8353000
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6464000
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1807000
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1717000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10160000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	133391000
CY2019	fgen	Number Of Regulatory Milestones NumberOfRegulatoryMilestones	2
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	144894000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	143107000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	111247000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	100364000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	33647000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42743000
CY2020	us-gaap	Depreciation Depreciation	11700000
CY2019	us-gaap	Depreciation Depreciation	11100000
CY2018	us-gaap	Depreciation Depreciation	6600000
CY2020Q4	fgen	Accrued Preclinical And Clinical Trial Current AccruedPreclinicalAndClinicalTrialCurrent	44113000
CY2019Q4	fgen	Accrued Preclinical And Clinical Trial Current AccruedPreclinicalAndClinicalTrialCurrent	16279000
CY2020Q4	fgen	Accrued Active Pharmaceutical Ingredient Product Price Adjustment Current AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent	0
CY2019Q4	fgen	Accrued Active Pharmaceutical Ingredient Product Price Adjustment Current AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent	36324000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	22800000
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	19784000
CY2020Q4	fgen	Accrued Contract Liabilities To Pharmaceutical Distributors Current AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent	15137000
CY2019Q4	fgen	Accrued Contract Liabilities To Pharmaceutical Distributors Current AccruedContractLiabilitiesToPharmaceuticalDistributorsCurrent	0
CY2020Q4	fgen	Accrued Co Promotion Expenses Current AccruedCoPromotionExpensesCurrent	11537000
CY2019Q4	fgen	Accrued Co Promotion Expenses Current AccruedCoPromotionExpensesCurrent	0
CY2020Q4	fgen	Accrued Profit Share Current AccruedProfitShareCurrent	7007000
CY2019Q4	fgen	Accrued Profit Share Current AccruedProfitShareCurrent	0
CY2020Q4	fgen	Property Taxes And Other Current PropertyTaxesAndOtherCurrent	5970000
CY2019Q4	fgen	Property Taxes And Other Current PropertyTaxesAndOtherCurrent	2044000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4869000
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4842000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	8088000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4543000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	119521000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	83816000
CY2019Q4	fgen	Accrued Active Pharmaceutical Ingredient Product Price Adjustment Current AccruedActivePharmaceuticalIngredientProductPriceAdjustmentCurrent	36300000
CY2020Q4	fgen	Accrued Long Term Co Promotion Liability Current AccruedLongTermCoPromotionLiabilityCurrent	11500000
CY2020Q4	fgen	Accrued Long Term Co Promotion Liability Non Current AccruedLongTermCoPromotionLiabilityNonCurrent	27424000
CY2019Q4	fgen	Accrued Long Term Co Promotion Liability Non Current AccruedLongTermCoPromotionLiabilityNonCurrent	53071000
CY2020Q4	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	8675000
CY2019Q4	us-gaap	Deferred Tax And Other Liabilities Noncurrent DeferredTaxAndOtherLiabilitiesNoncurrent	8913000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	853000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	942000
CY2020Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	2690000
CY2019Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	2481000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	39642000
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	65407000
CY2020	fgen	Number Of Product Development Obligations NumberOfProductDevelopmentObligations	11
CY2020Q4	fgen	Accrued Product Development Costs Excluding Interest AccruedProductDevelopmentCostsExcludingInterest	11600000
CY2019Q4	fgen	Accrued Product Development Costs Excluding Interest AccruedProductDevelopmentCostsExcludingInterest	10600000
CY2020Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	7100000
CY2019Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	6200000
CY2020Q4	us-gaap	Contractual Obligation ContractualObligation	86000000.0
CY2020Q4	us-gaap	Recorded Unconditional Purchase Obligation Due Within One Year RecordedUnconditionalPurchaseObligationDueWithinOneYear	42012000
CY2020Q4	us-gaap	Recorded Unconditional Purchase Obligation Due In Second Year RecordedUnconditionalPurchaseObligationDueInSecondYear	44014000
CY2020Q4	us-gaap	Recorded Unconditional Purchase Obligation RecordedUnconditionalPurchaseObligation	86026000
CY2020	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one vote
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	91441000
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	87657000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9290000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10018000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1893000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1483000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	7910000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	7725000
CY2020Q4	fgen	Common Stock Shares Reserved CommonStockSharesReserved	114604000
CY2019Q4	fgen	Common Stock Shares Reserved CommonStockSharesReserved	110220000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10018000
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	26.63
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2692000
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	31.55
CY2020	fgen	Stock Issued During Period Shares Stock Options Exercised Full Year StockIssuedDuringPeriodSharesStockOptionsExercisedFullYear	3113000
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	10.73
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	73000
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	39.92
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	234000
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	40.11
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9290000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	32.94
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	86013000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	8929000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	32.76
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	84125000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5576000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	29.50
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	66943000
CY2020	us-gaap	Restricted Stock Shares Issued Net Of Shares For Tax Withholdings RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings	526055
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	29.99
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	54.74
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	53.69
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	72720000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	66267000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	52142000
CY2019	fgen	Class Of Warrant Or Right Number Of Warrants Or Rights Exercised During Period ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercisedDuringPeriod	4430
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7564000
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9050000
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8834000
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2900000
CY2020	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.60
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3200000
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3000000.0
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-195617000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	2538000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-38472000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	6686000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-79180000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-47644000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-188931000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-76642000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-86116000
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2000
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	360000
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	328000
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	302000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	360000
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	328000
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	304000
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2019	fgen	Effective Income Tax Rate Reconciliation Net Operating Losses Not Benefitted EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted	-0.029
CY2018	fgen	Effective Income Tax Rate Reconciliation Net Operating Losses Not Benefitted EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted	-0.232
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.007
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.217
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.116
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	-0.008
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	-0.025
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	-0.005
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.003
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	360000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	328000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	304000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0
CY2020	fgen	Effective Income Tax Rate Reconciliation Deduction Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost	0.024
CY2019	fgen	Effective Income Tax Rate Reconciliation Deduction Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost	0.063
CY2018	fgen	Effective Income Tax Rate Reconciliation Deduction Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationDeductionExpenseShareBasedCompensationCost	0.145
CY2020	fgen	Effective Income Tax Rate Reconciliation Benefit On Intercompany Transfer Of Assets EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets	0.417
CY2019	fgen	Effective Income Tax Rate Reconciliation Benefit On Intercompany Transfer Of Assets EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets	0
CY2018	fgen	Effective Income Tax Rate Reconciliation Benefit On Intercompany Transfer Of Assets EffectiveIncomeTaxRateReconciliationBenefitOnIntercompanyTransferOfAssets	0
CY2020	fgen	Effective Income Tax Rate Reconciliation Valuation Allowance On Intercompany Transfer Of Assets EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets	-0.417
CY2019	fgen	Effective Income Tax Rate Reconciliation Valuation Allowance On Intercompany Transfer Of Assets EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets	0
CY2018	fgen	Effective Income Tax Rate Reconciliation Valuation Allowance On Intercompany Transfer Of Assets EffectiveIncomeTaxRateReconciliationValuationAllowanceOnIntercompanyTransferOfAssets	0
CY2020	fgen	Effective Income Tax Rate Reconciliation Net Operating Losses Not Benefitted EffectiveIncomeTaxRateReconciliationNetOperatingLossesNotBenefitted	-0.232
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.006
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.006
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.002
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.004
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.004
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	134033000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	91267000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	62465000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	52243000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	32417000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	37786000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	10399000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	11159000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	8243000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	10698000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	5875000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	5353000
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	13550000
CY2019Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	13323000
CY2020Q4	fgen	Deferred Tax Assets Intangible Assets DeferredTaxAssetsIntangibleAssets	75915000
CY2019Q4	fgen	Deferred Tax Assets Intangible Assets DeferredTaxAssetsIntangibleAssets	0
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	284000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	342897000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	222113000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	337824000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	213847000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	5073000
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	8266000
CY2020Q4	fgen	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	5073000
CY2019Q4	fgen	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	8266000
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0
CY2019Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	5073000
CY2019Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	8266000
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	124000000.0
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	19900000
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	34400000
CY2020Q4	us-gaap	Deferred Tax Asset Intra Entity Transfer Asset Other Than Inventory DeferredTaxAssetIntraEntityTransferAssetOtherThanInventory	78700000
CY2020	fgen	Experience Historical Ownership Changes ExperienceHistoricalOwnershipChanges	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	48600000
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	500000
CY2020	us-gaap	Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Estimated Range Not Possible SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleEstimatedRangeNotPossible	The Company does not anticipate a material change to its unrecognized tax benefits over the next twelve months that would affect the Company’s effective tax rate.
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2020	us-gaap	Revenues Revenues	176319000
CY2019	us-gaap	Revenues Revenues	256577000
CY2018	us-gaap	Revenues Revenues	212958000
CY2020Q4	us-gaap	Inventory Net InventoryNet	16530000
CY2019Q4	us-gaap	Inventory Net InventoryNet	6887000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	33647000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	42743000
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	29606000
CY2019Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	39602000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2043000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1931000

Files In Submission

Name	View Source	Status
0001564590-21-009871-index-headers.html	Edgar Link	pending
0001564590-21-009871-index.html	Edgar Link	pending
0001564590-21-009871.txt	Edgar Link	pending
0001564590-21-009871-xbrl.zip	Edgar Link	pending
fgen-10k_20201231.htm	Edgar Link	pending
fgen-10k_20201231_htm.xml	Edgar Link	completed
fgen-20201231.xsd	Edgar Link	pending
fgen-20201231_cal.xml	Edgar Link	unprocessable
fgen-20201231_def.xml	Edgar Link	unprocessable
fgen-20201231_lab.xml	Edgar Link	unprocessable
fgen-20201231_pre.xml	Edgar Link	unprocessable
fgen-ex1035_604.htm	Edgar Link	pending
fgen-ex1036_605.htm	Edgar Link	pending
fgen-ex1044_204.htm	Edgar Link	pending
fgen-ex211_241.htm	Edgar Link	pending
fgen-ex231_10.htm	Edgar Link	pending
fgen-ex311_14.htm	Edgar Link	pending
fgen-ex312_9.htm	Edgar Link	pending
fgen-ex321_13.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gapk0ju0ozex000001.jpg	Edgar Link	pending
gapk0ju0ozex000002.jpg	Edgar Link	pending
gapk0ju0ozex000003.jpg	Edgar Link	pending
gapk0ju0ozex000004.jpg	Edgar Link	pending
gapk0ju0ozex000005.jpg	Edgar Link	pending
gapk0ju0ozex000006.jpg	Edgar Link	pending
gapk0ju0ozex000007.jpg	Edgar Link	pending
gapk0ju0ozex000008.jpg	Edgar Link	pending
gapk0ju0ozex000009.jpg	Edgar Link	pending
gapk0ju0ozex000010.jpg	Edgar Link	pending
gapk0ju0ozex000011.jpg	Edgar Link	pending
gapk0ju0ozex000012.jpg	Edgar Link	pending
gs4n3b54niev000001.jpg	Edgar Link	pending
gs4n3b54niev000002.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FGEN
FIBROGEN INC Stock $fgen

2020 Q4 Form 10-K Financial Statement

#000156459021009871 Filed on March 01, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FGEN FIBROGEN INC Stock $fgen

2020 Q4 Form 10-K Financial Statement

#000156459021009871 Filed on March 01, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FGEN
FIBROGEN INC Stock $fgen